Evolus licenses a toxin. They have no therapeutic program. They launched years before Daxxify. To compare expenses now is completely disingenuous. It's true Revance has overspent but they can and will cut expenses. If 3 years from now the situation hasn't changed then you will have been right—I doubt it.
Meanwhile, Daxxify is starting to blow up on social media.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.